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Abstract
RATIONALE: Treatment of glioblastoma (GBM) remains challenging due in part to its histologic intratumoral
heterogeneity that contributes to its overall poor treatment response. Our goal was to evaluate a voxel-based bio-
marker, the functional diffusion map (fDM), as an imaging biomarker to detect heterogeneity of tumor response in
a radiation dose escalation protocol using a genetically engineered murine GBM model. EXPERIMENTAL DESIGN:
Twenty-four genetically engineered murine GBM models [Ink4a-Arf−/−/Ptenloxp/loxp/Ntv-a RCAS/PDGF(+)/Cre(+)]
were randomized in four treatment groups (n = 6 per group) consisting of daily doses of 0, 1, 2, and 4 Gy delivered
for 5 days. Contrast-enhanced T1-weighted and diffusion-weighted magnetic resonance imaging (MRI) scans were
acquired for tumor delineation and quantification of apparent diffusion coefficient (ADC) maps, respectively. MRI
experiments were performed daily for a week and every 2 days thereafter. For each animal, the area under the
curve (AUC) of the percentage change of the ADC (AUCADC) and that of the increase in fDM values (AUCfDM+)
were determined within the first 5 days following therapy initiation. RESULTS: Animal survival increased with
increasing radiation dose. Treatment induced a dose-dependent increase in tumor ADC values. The strongest
correlation between survival and ADC measurements was observed using the AUCfDM+ metric (R
2 = 0.88).
CONCLUSION: This study showed that the efficacy of a voxel-based imaging biomarker (fDM) was able to detect
spatially varying changes in tumors, which were determined to be a more sensitive predictor of overall response
versus whole-volume tumor measurements (AUCADC). Finally, fDM provided for visualization of treatment-associated
spatial heterogeneity within the tumor.
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Introduction
Glioblastoma (GBM) is the most common and malignant form of
primary brain tumor in adults [1]. Standard therapy for treating
patients with GBM is a combination of maximal safe surgical resec-
tion with chemotherapy and radiotherapy [2,3]. The prognosis for
patients with GBM is generally poor with an average survival time
of 51 weeks [4]. Assessment of response to therapy is based on the
measurement of the tumor size 8 to 10 weeks after the start of treat-
ment [5]. Because of poor patient outcomes associated with limited
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survival time, there is a clinical need for the development of quanti-
tative imaging biomarkers that can provide early stratification of
treatment efficacy.
Magnetic resonance imaging (MRI) is able to noninvasively acquire
a wide range of brain tumor characteristics (morphologic and physi-
ological) and has become the technique of choice for assessing thera-
peutic response [6]. MRI is routinely employed to estimate tumor
volume using anatomic images but also tumor-associated edema
and tumor cellularity using the apparent diffusion coefficient
(ADC) of water calculated using diffusion-weighted (DW) MRI
sequences [7–10]. Diffusion imaging has been successfully used to
assess glioma response to different chemotherapies [9,11,12] as well
as radiotherapy [12]. Taken together, these studies have shown that
DW-MRI is a sensitive biomarker that is capable of detecting early
cellular changes in treated tumors, which precede macroscopic volu-
metric response. Whole-tumor analysis is the most common technique
for assessing therapeutic response, typically comparing differences in
mean tumor ADC values post-therapy (or mid-therapy) to the pre-
therapy values. However, several studies have shown that diffusion
changes could both increase and decrease over time within the same
tumor, which is a consequent of the highly heterogeneous response
of GBMs to treatment [13–15]. Assessing the mean change in overall
tumor ADC value can lead to a diminution of sensitivity of the ADC
measure because of divergent (increase/decrease) changes in tumor
ADC values in response to treatment.
Assessing therapeutic response in patients with glioma using ADC
maps observed that tumor reaction to cytotoxic treatment was spa-
tially dependent [14]. This led our group to develop the first voxel-
based approach called the functional diffusion map (fDM) using
registered longitudinal diffusion ADC maps [14–16]. The voxel-
by-voxel analysis approach has distinct advantages over whole-tumor
volume techniques such as histogram analysis, as it allows for clas-
sification of individual tumor voxels based on the extent of change
in ADC values during therapy [14]. We have demonstrated the
efficacy of fDM as an early surrogate biomarker of survival in brain
tumor as well as in the 9L rodent glioma model undergoing chemo-
therapy [15,16].
In the current study, whole-tumor volume percent change in mean
ADC values was compared with fDM metrics following radiation
treatment using a genetically engineered murine GBM model to eval-
uate these approaches as imaging biomarkers of tumor response. The
GBM model was found to have a heterogeneous pattern of response
similar to that observed in clinical subjects, where regions within the
tumor increased and decreased in ADC values during treatment.
Compared to the histogram-based approach, the fDM biomarker
was determined to provide the most predictive metric correlated to
overall survival following radiation therapy and in a dose-dependent
manner. Overall, the fDM biomarker approach has potential broad
applications in both preclinical drug development settings as well as
for translational clinical trials and individualized patient management.
Materials and Methods
Cell Culture
DF-1 cells were purchased from ATCC (Manassas, VA). Cells were
grown at 39°C according to ATCC instructions. RCAS–PDGF-B–HA
and RCAS-Cre, provided by Dr E. Holland, have been described
previously [15,17–19]. Transfections with RCAS–PDGF-B–HA
or RCAS-Cre were performed using FuGENE 6 transfection kit
according to the manufacturer’s instructions (Roche Applied Science,
Indianapolis, IN). Expression of PDGF and Cre was confirmed by
Western blot analysis of the HA-HRP antibody (Sigma, St Louis,
MO) and Cre (Berkeley Antibody, Richmond, CA).
Intracranial Inoculation
The University of Michigan Laboratory Animal (ULAM) Com-
mittee approved the use of animals for this study. Generation of the
Nestin-tv-a, Ink4a-Arf−/−/, Ptenloxp/loxp mouse lines has previously been
described [15–19]. Animals were originally acquired from E. Holland
and inbred at the University of Michigan ULAM facility. Intracranial
inoculation was performed on 4- to 6-week-old transgenic mice
(Nestin-tv-a, Ink4a-Arf−/−/, Ptenloxp/loxp). Mice were anesthetized with
a ketamine/xylazine (0.1/0.02 mg/kg) mixture and prepped with top-
ical antiseptic before cell injection. A 1-μl suspension containing 8 ×
104 cells with an equal number of RCAS–PDGF-B– and RCAS-
Cre–transfected DF1 cells was delivered using a 30-gauge needle
attached to a Hamilton syringe and stereotactic fixation device
(Stoelting, Wood Dale, IL) at coordinates of 1.5 mm (bregma) and
0.5 mm (lateral) and a depth of 1.5 mm.
Treatment
Following intracranial inoculation, tumor volumes were moni-
tored over time using contrast-enhanced (CE) T1-weighted MRI
as described below. Once tumor volumes reached 20 to 40 mm3,
pre-treatment MRI images were acquired and treatment was initiated
on day 0. Animals (n = 40) were randomized into four different
groups (n = 10 per group) as follows: sham-treated (0 Gy) and 5,
10, and 20 Gy total ionizing radiation (IR) doses that were delivered
by fractionated doses over a 5-day period (0, 1, 2, and 4 Gy/day,
respectively). Through the duration of the study, several of the mice
encountered untimely attrition unrelated to treatment or tumor
growth. Mice were sacrificed when they became moribund or tumor
size exceeded 200% of their baseline volume (20-40 mm3).
MRI Scans
MRI scans were performed on a 9.4-T, 16-cm horizontal bore
(Agilent Technologies, Inc, Santa Clara, CA) Direct Drive System
with a mouse head quadrature volume coil (m2m Imaging, Corp,
Cleveland, OH) or mouse surface receive coil actively decoupled to
a whole-body volume transmit coil (RAPID MR International, LLC,
Columbus, OH). Throughout the MRI experiments, animals were
anesthetized with 1% to 2% isoflurane/air mixture, and body temper-
ature was maintained using a heated air system (Air-Therm Heather;
World Precision Instruments, Sarasota, FL).
MRI was performed on mice to quantify tumor volumes over time
along with tumor water diffusion values. Delineation of tumor tissue
from healthy brain was accomplished using CE T1-weighted spin-
echo MRIs with the following parameters: repetition time/echo time =
510/15 ms, field of view = 20 × 20 mm2, matrix size = 128 × 128, slice
thickness = 0.5 mm, 25 slices, and two averages. Total acquisition time
was 2minutes and 12 seconds. Contrast enhancement was performed by
i.p. administration of 50 μl of 0.5 M gadolinium-DTPA (Magnevist;
Bayer Healthcare Pharmaceuticals, Wayne, NJ) 5 minutes before acqui-
sition initiation. Tumor ADC maps were obtained from a diffusion-
weighted spin-echo sequence, equipped with a navigator echo for
motion correction and gradientwaveforms sensitive to isotropic diffusion,
with the following parameters: repetition time/echo time = 2000/37 ms,
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field of view = 20 × 20 mm2, matrix size = 128 × 64, slice thickness =
0.5 mm, 25 slices, two averages, diffusion time = 40 ms, gradient pulse
width=10ms, and b values (diffusionweighting) of 0, 120, and1200 s/mm2.
Total acquisition time was 8 minutes and 32 seconds.
CE-MRI and DW-MRI were acquired daily between day 0 and
day 5 for all animals under study. At day 5, four animals per group
were sacrificed following the MRI session for histology (see below).
The 24 remaining animals (six per group) were monitored by CE-
MRI every other day to quantify tumor volume changes over time.
Image Reconstruction and Analyses
Tumors were manually contoured along the enhancing rim of the
tumors on the CE T1-weighted images. These tumor volumes of
interest were used to calculate tumor volume and whole-tumor
means of ADC and delineate the tumor volume for fDM analysis.
ADC maps were calculated from the two diffusion-weighted
images using the following equation:
ADC = ln
S1
S2
 
= b2 − b1ð Þ;
where S1 and S2 are the diffusion-weighted images at b values b1 and
b2, respectively, and ADC is the apparent diffusion coefficient obtained
using b1 and b2. All image reconstruction and digital image analyses
were accomplished using in-house programs developed in Matlab
(The Mathworks, Natick, MA).
In brief, fDM analysis was accomplished in the following three steps:
computation of temporally resolved quantitative ADC maps, image
registration of serial ADCmaps followed by classification of voxel-based
ADC changes based on predetermined thresholds. Mid-treatment CE
images and all ADC maps were spatially aligned to the pre-treatment
CE image using a stepwise image registration approach. Initial registra-
tion of serial MRI scans to the baseline scan (day 0) was performed
assuming a rigid-body geometry relationship to provide for rapid align-
ment of the head using an initial set of four control points. Next,
images were co-registered using a thin-plate spline transformation that
was optimized using mutual information as an objective function and
Nelder-Mead simplex as an optimizer [20]. This process required an
additional set of control points that were automatically placed within
the tumor volume based on the size and information content of the
tumor. Degrees of freedom of the final transform were 36 to 72.
The fDM data were determined by first calculating the difference
between the ADC within the tumor before therapy and at each mid-
treatment time point. Red voxels represent the tumor volume where
ADC value increased beyond the user-defined ADC threshold of
0.2 × 10−3 mm2/s (described below), blue voxels represent volumes
whose ADC decreased by more than 0.20 × 10−3 mm2/s, and the
green voxels represent voxels within the tumor that were unchanged
(that is, the absolute value of ΔADC was <0.20 × 10−3 mm2/s). All
voxels within a classification were summed and normalized to total
tumor volume to generate three volume fractions: fDM+ (increased
ADC, denoted red), fDM− (decreased ADC, denoted blue), and
fDM0 (unchanged ADC, denoted green). Calculation of the fDM
thresholds for voxel classification has been previously described
[21]. Briefly, we empirically calculated the thresholds that designate
a significant change in ADC within a voxel from five untreated tumors.
For each animal, we used the tumor region of interest before and 1 day
after therapy initiation. Combining the data from all five subjects, we
performed linear least-squares regression analysis on the pre-treatment
and intra-treatment ADC values. We then determined the 95% con-
fidence intervals from the resulting linear least-squares analysis. The
threshold obtained was 0.20 × 10−3 mm2/s (data not shown).
In addition to analyzing the metrics at each time point, the area
under the curve (AUC) between day 0 and day 5 (24 hours after the
last therapy) were calculated for both the percentage change of ADC
(AUCADC) and for the fDM metrics (AUCfDM).
Immunohistochemistry
For each of the treatments, three animals from each group were
sacrificed at day 5 (24 hours after the last treatment), and tumors
were harvested and fixed in 10% neutral buffered formalin for at least
48 hours. Tumors were sectioned and paraffin embedded, and 5-μm
sections were cut onto slides. Paraffin was removed in xylene, and
slides were rehydrated through gradually decreasing alcohol con-
centrations 2 min/step before ending in tap water (100% ethanol,
95% ethanol, 70% ethanol, water). The slides were stained with
H&E (cell viability), Ki-67 antibody (cell proliferation), and ApopTag
(apoptosis) after antigen retrieval with Diva (Biocare, Concord, CA)
using the Avidin/Biotin Complex System (Vectastain; Vector Labs,
Burlingame, CA) and discolored with the DAB solution (Vector Labs).
Nontreated or treated brain tumor sections were imaged at the
same magnification using an Olympus microscope and subjected
to quantitative analysis. Because of the heterogeneous nature of the
tumors, Ki-67 and apoptosis indices were quantified using the high-
est staining area. Briefly, staining was checked under low magnifica-
tion, and then the highest staining area was identified. The image
was taken at ×80, and then Ki-67–positive or ApopTag+ cells and
total cells were counted by ImageJ.
Statistics
Overall survival of the treatment groups was assessed by log-rank
tests and Kaplan-Meier survival curves. Group comparisons of MRI
and immunohistologic results were determined at individual time
points using analysis of variance (ANOVA) and least-squares differ-
ence to correct for multiple comparisons. A Pearson correlation anal-
ysis was used to determine linear relationships between imaging
biomarkers and overall survival. Immunologic differences between
groups were assessed using two-tailed Student’s t test in Prism 6
(GraphPad Software, Inc, La Jolla, CA). All other statistical compu-
tations were performed with a statistical software package (SPSS Soft-
ware Products, Chicago, IL). Statistical significance was assessed at
P < .05. All results were presented as means ± SEM.
Results
Survival and Tumor Growth
A Kaplan-Meier survival plot for all treatment groups revealed a
dose-dependent increase in animal survival (Figure 1A). All groups
were found to have significantly different survival post-therapy (P <
.05). The median survival time of untreated (0 Gy) and 1, 2, and 4 Gy
groups was 3.6 ± 0.2, 7.2 ± 1.2, 13.8 ± 1.5, and 21.5 ± 1.5 days,
respectively (Figure 1A).
A plot of the percentage change in tumor volumes for all groups as a
function of time post-treatment initiation is presented in Figure 1B.
The volume of untreated tumors increased rapidly and by day 4
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reached the criteria for removal from the study (260 ± 33%). At 2 days
post-treatment initiation, the percentage change of the tumor size of
the untreated group was significantly higher compared to all the treated
groups (129 ± 6% versus 53.5 ± 18%, 31.5 ± 22%, and −9 ± 8% for the
untreated and 1, 2, and 4 Gy groups, respectively; P < .05). The per-
centage change of tumor size of the 1 Gy group was statistically differ-
ent from all other treatment groups at day 4 (117 ± 33% versus 14 ±
20% and −46 ± 5% for the 1 Gy versus 2 and 4 Gy groups, respectively;
Figure 1. (A) Kaplan-Meier survival plots are presented for each therapy (0, 1, 2, and 4 Gy). The median survival for these groups was 4, 7,
11, and 19 days post-therapy, respectively. All groups were significantly different, as determined by log-rank test (P< .05). (B) Percentage
change of tumor volumes for 0, 1, 2, and 4 Gy groups assessed by MRI as a function of time. Data are presented as the means ± SEM.
Figure 2. (A) Representative MRIs of each group acquired at time of maximum percentage change in mean ADC. The times were day 4 and
day 7, day 11, and day 23 for untreated and 1, 2, and 4Gy, respectively.MRI data consist of ADC percent change images (colormaps) overlaid
on the anatomic CE T1-weighted images. ADC percent change images were generated by calculating the percentage change of ADC values
on a voxel-by-voxel basis using registeredmid-treatment and pre-therapy ADCmaps. (B) Plots of the percentage change in ADC as a function
of time for each treatment group. (C) AUC of the percentage change in ADCmeasured during the therapy (day 0 to day 5) for each treatment
group (means ± SD). All groups were significantly different, as determined by ANOVA followed by an Least Significance Difference (LSD)
correction test (P< .05). (D) Scatter plot and linear regression of theAUCof the percentage changeofADCvaluemeasuredduring the therapy
(day 0 to day 5) as a function of the overall survival. Each dot represents an individual animal. Data are presented as the means ± SEM.
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P < .05). In addition, the 2 and 4 Gy doses were also significant from
each other at day 4 (P < .05).
Treatment-Induced Percentage Change in Tumor ADC Values
We observed large spatial variation in tumor ADC values at peak
response (i.e., maximum percentage change in mean ADC) for each
group post-treatment initiation (Figure 2A). When analyzing the
whole-tumor ADC metric at each time point, the percentage change
in mean ADC values in the 2 and 4 Gy groups were significantly
higher than the untreated group 2 days post-treatment initiation
(12.1 ± 3.1% and 10.2 ± 3.3% versus 0.6 ± 2.4%, respectively, P <
.05; Figure 2B). By day 3, the percentage change in tumor ADC
values increased significantly in the 1 Gy group compared to the
untreated group (3.1 ± 2.6% versus −5.2 ± 3.2%, P < .05; Figure 2B).
Despite the elevated ADC values from baseline in the 2 Gy group
over the 4 Gy treated group, no significant differences were observed
(Figure 2B). All treated groups generated AUCADC values that were
significantly higher than the untreated group (−27.8 ± 15.5% versus
23.0 ± 12.9%, 52.8 ± 8.4%, and 44.7 ± 11.3%, for the untreated
and 1, 2, and 4 Gy groups, respectively, P < .05; Figure 2C ). In addi-
tion, AUCADC correlated with overall survival (R
2 = 0.46, P = .002;
Figure 2D).
The fDM as an Imaging Biomarker of Survival
Analysis by fDM of the same representative animals displayed in
Figure 2 showed regions of tumor with elevated ADC values from
baseline that increased with radiation dose [Figure 3A; red voxels
(fDM+)]. Although the number of fDM+ voxels in the 1 Gy group
were higher than the untreated group at each of the time points, this
difference was not significant with near significance occurring at
day 5 (1.6 ± 0.4 versus 11.3 ± 2.0, for the untreated and 1 Gy groups,
respectively, P = .055; Figure 3B). When compared to untreated
animals, significant differences in fDM+ for 2 and 4 Gy groups were
observed as early as day 2 (2.5 ± 0.6% versus 12.7 ± 4.5%, P < .05)
and day 1 (2.2 ± 085% versus 7.1 ± 2.5%, P < .05), respectively.
Despite the fact that for all time points the fDM+ values of the
4 Gy group were higher than those measured in the 2 Gy group,
significant differences were observed at day 1 and day 3 only (7.1 ±
2.5% versus 2.0 ± 0.7% and 22.7 ± 3.2% versus 9.5 ± 1.7%, respec-
tively; Figure 3B). We observed an increase of AUCfDM+ values in a
Figure 3. (A) fDM overlays of the same representative animals and time points used in Figure 2A. fDM images (color maps) are overlaid
on anatomic CE T1-weighted images. Images of fDMs reveal red voxels, which are regions with significant increases in ADC, and blue
voxels, which are regions within the tumor with significantly decreased ADC values. The green voxels are tumor regions wherein the
ADC values did not change (over the defined threshold level of ±0.2 × 10−9 m2/s). (B) Plots of the fDM increases (fDM+) as a function
of time for each treatment group. Data are presented over the first 5 days of treatment as the means ± SD. (C) AUC of the fDM+
measured during the therapy (day 0 to day 5) for each treated group (means ± SD). All groups were significantly different, as determined
by ANOVA followed by an LSD correction test (P < .05). (D) Scatter plot and linear regression of the AUC of the fDM+ value measured
during the therapy (day 0 to day 5) as function of the overall survival. Each dot represents an individual animal. Data are presented as the
means ± SEM.
558 Diffusion-Weighted MRI as a Biomarker Lemasson et al. Translational Oncology Vol. 6, No. 5, 2013
radiation dose–dependent way (10.6 ± 2.1%, 33.4 ± 8.7%, 56.7 ±
6.2%, and 90.4 ± 10.1% for the 0, 1, 2, and 4 Gy, respectively;
Figure 3C ). AUCfDM+ was statistically different between each group
(P < .05; Figure 3C ) with a strong correlation to overall survival (R2 =
0.88, P = 9.3 × 10−8; Figure 3D).
Immunohistochemical Evaluation of In Vivo
GBM Treatment Effects
To study the effects of radiation dose on tumor cell morphology,
proliferation, and apoptosis, intracranial tumors harvested at day 5
(24 hours after the last treatment) were subjected to immunohisto-
chemical analysis. Tumors displayed findings similar to human GBM,
including nuclear atypia, mitotic figures, areas of necrosis, and vascular/
endothelial proliferation (Figure 4A). Untreated tumors displayed low
percentage of apoptotic cells (Figure 4B). We observed an increase in
apoptotic cells in the three treated groups compared to the untreated
group (Figure 4, A and B). In contrast, a significant dose-dependent
decrease in tumor proliferation, as measured by Ki-67, was observed
in each of the treated groups compared to untreated animals (Figure 4,
A and C ).
Discussion
High-grade gliomas are markedly heterogeneous in their morphologic
and genetic nature. As such, they demonstrate a spatially hetero-
geneous response to cytotoxic and radiation therapies with tumor
regions developing elevated levels of edema, necrosis, and angio-
genesis adding difficulty in ascertaining treatment efficacy. Advanced
quantitative MRI techniques, such as DW-MRI, have shown promise
as a robust approach for response monitoring of tumors by focusing
on a specific feature of the tumor, in this case tumor cellularity.
Although physiological changes within the tumor following therapy
can be visualized by quantitative MRI, the use of these techniques
as a surrogate biomarker of patient survival continues to be hampered
due to uncertainties in knowing how to optimally analyze the data to
provide for the most predictive metric [8].
The traditional method of analyzing quantitative images is to
calculate a scalar quantity, i.e., mean or median, that represents the
physiological state of the entire tumor volume at a given time point. A
positive or negative response of the tumor following a therapeutic
intervention can be inferred from the percentage change in the quan-
titative scalar value, thus providing a biomarker for patient survival
prediction that can be used as a surrogate to a meaningful clinical
end point. Although this technique can be applied quickly and easily
by simply contouring the tumor volume, in our study this metric
yielded only a limited correlation with overall survival. Statistical-
based approaches that rely on whole-tumor values may not provide
enough sensitivity for detection of treatment-induced changes when
the underlying changes within the tumor mass are heterogeneous,
which results in attenuation of the biomarker metric, thus hampering
detection of overall therapeutic response.
However, voxel-based approaches that employ a classification
scheme, i.e., fDM, provide a unique opportunity to fully use the
morphologic information contained within the temporally resolved
quantitative maps, i.e., ADC, for response assessment. The fact that
fDM can separate the response heterogeneity within the tumor into
Figure 4. Dose-dependent response of IR treatment. (A) Representative images showing the proliferation and apoptosis of tumor cells
under different dose of IR treatment. (B) The percentage of apoptotic cells (ApopTag+) was quantified (40× area) among different doses
of IR treatments (mice of each group: n = 3). (C) The percentage of proliferative cells (Ki-67+) were quantified (40× area) among dif-
ferent doses of IR treatments (mice of each group: n = 3). Data are presented as the means ± SEM.
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discrete classes of increased, decreased, or unchanged ADC values
eliminates the attenuation that typically occurs in whole-tumor anal-
ysis approaches. Moreover, the fDM approach also allows delineation
of the most predictive response metric, which for fDM is the relative
tumor volume with increasing ADC (fDM+). Through voxel-based
techniques, individual classifications can each be thoroughly evaluated
as predictive biomarkers, each of which provides distinctive information
related to the morphologic or physiological changes occurring within
the tumor mass during therapy [14,16,21–23].
In the present study, we report only a 10% increase in the percent-
age change of tumor ADC following 2 and 4 Gy doses with little to
no difference between these groups (Figure 2B). Although consistent
with previous studies [15,24,25], the weak correlation between the
whole-tumor ADC metric and overall survival (Figure 2D) was
attributed to the tumor response heterogeneity in the GBM model.
In contrast, applying fDM to the ADC maps and focusing on the
most robust response metric, i.e., fDM+, we were able to improve
our detection of dose-dependent trends in tumor response
(Figures 2B and 3B). Calculation of AUC of fDM over the 5-day
fractionated therapy was also found to be strongly correlated to over-
all survival (Figure 3D) as well as generating dose-dependent trends
(Figure 3C ) that were inversely related to those observed in the tumor
proliferative potential as determined by Ki-67 staining (Figure 4C ).
We have reported previously similar correlations between fDM and
histologic findings [15,19].
A vital part of fDM is the use of image co-registration. Deformable
registration was performed in this study to spatially align temporally
resolved MRI data, CE-MRI and ADC maps, for fDM analysis.
Imaging data were acquired as late as 5 days post-treatment initia-
tion. As observed in Figure 1B, significant changes in tumor volume
had occurred over this time period with volumes increasing up to
300% for untreated animals and decreasing by up 50% for 4 Gy
treated animals. However, fDM voxel–based analysis can still be used
effectively, as it is not necessary to assume that tumor cells within a
given voxel pre-treatment are the same at a later time interval, but
rather like structures exist pre-treatment and mid-treatment, which
can be used to align and register regions spatially within the tumor
mass during therapeutic intervention. The registration algorithm
employed in this study uses mutual information as the objective
function, thus like structures within image data sets drive the regis-
tration of the data between interval scans even in the presence of
large volumetric changes. If serial data were misregistered or random,
fDM results would correspondingly be erroneous, thus correlation of
the fDM+ biomarker metric to response would be unlikely to be
observed. In fact, in this study, we found a stronger outcome cor-
relation with fDM+ (Figure 3D) versus whole-volume tumor averages
(Figure 2D). Moreover, the quantified histologic data also support
the underlying changes in tumor diffusion values (Figure 4). These
data reveal the robust and accurate nature of voxel-based longitudinal
measures for use in image analysis for the purpose of detecting
spatially varying treatment effects.
It is known that genotypic and phenotypic diversities within a
tumor mass can greatly influence its growth and response to therapy
[26]. Imaging biomarkers such as fDM have the potential to provide
rapid and objective/quantitative information related to tumor treat-
ment response. Spatial variations with respect to tumor sensitivity to
a treatment intervention would be anticipated to be observable by
the fDM biomarker. Red-encoded voxels would indicate regions
within the tumor that are responding, whereas green/blue voxels
would be anticipated to be regions that are unresponsive. Spatially
distinctive regions exhibiting either up-front resistance or rapid emer-
gence of a resistant cell population can potentially be detectable using
the fDM biomarker. In fact, DW-MRI has been shown to be sensi-
tive enough to detect real-time emergence of resistance in an animal
tumor model [27]. Further validation of the fDM imaging biomarker
will be required for determining the net impact of delineating spa-
tially varying treatment-associated changes in tumor structure and
function. However, it is reasonable to assume that the use of voxel-
based biomarkers will advance our ability to more effectively treat
patients with cancer.
In summary, we demonstrated that MR diffusion imaging, when
analyzed using a voxel-based technique, was more sensitive than
whole-tumor histogram-based metrics for assessing tumor tissue
changes induced by fractionated doses of ionizing radiation. More-
over, this study showed that the efficacy of a voxel-based imaging
biomarker (fDM) was able to detect spatially varying changes in
tumors that were determined to be a more sensitive predictor of
overall response versus whole-tumor measurements (AUCADC).
DW-MRI and associated fDMs provide for visualization of treatment-
associated intratumoral spatial heterogeneity in both preclinical and
clinical studies [14–16,23,28–31]. Possible future uses of fDM
include adaptive conformal targeting of external beam ionizing radia-
tion to specific tumor regions exhibiting resistance or spatial guidance
of drug injections. Overall, the application of voxel-based analysis
provides for both improved sensitivity for detection of changes and
three-dimensionally spatially resolved readouts of treatment-associated
changes, which is anticipated to improve patient outcomes.
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